ICU Medical (NASDAQ:ICUI) Stock Price Passes Above 200 Day Moving Average – Here’s Why

ICU Medical, Inc. (NASDAQ:ICUI) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $138.91 and traded as high as $157.64. ICU Medical shares last traded at $157.60, with a volume of 155,803 shares.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Piper Sandler cut their price objective on ICU Medical from $178.00 to $163.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Zacks Research raised ICU Medical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Finally, Needham & Company LLC upgraded ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Wednesday, May 27th. Three investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $168.40.

ICU Medical Stock Up 2.1%

The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. The stock’s fifty day simple moving average is $137.86 and its two-hundred day simple moving average is $138.91. The stock has a market capitalization of $3.94 billion, a P/E ratio of 85.19, a price-to-earnings-growth ratio of 2.16 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.78 by $0.19. The firm had revenue of $525.77 million during the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The company’s revenue for the quarter was down 12.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, research analysts expect that ICU Medical, Inc. will post 6.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of ICU Medical stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director directly owned 7,960 shares of the company’s stock, valued at approximately $978,363.60. The trade was a 23.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the transaction, the vice president directly owned 19,460 shares in the company, valued at $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On ICU Medical

Hedge funds have recently made changes to their positions in the stock. Norges Bank acquired a new stake in ICU Medical during the 4th quarter valued at approximately $58,083,000. Kirr Marbach & Co. LLC IN lifted its position in shares of ICU Medical by 18.4% in the 1st quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock worth $5,702,000 after purchasing an additional 6,863 shares during the period. Thrivent Financial for Lutherans boosted its stake in shares of ICU Medical by 1,604.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after purchasing an additional 285,648 shares during the last quarter. F m Investments LLC boosted its stake in shares of ICU Medical by 33.3% in the 4th quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock valued at $6,637,000 after purchasing an additional 11,608 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of ICU Medical by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock worth $387,313,000 after buying an additional 89,755 shares during the period. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.